CSL Limited (CSLLY)
USD 81.65
(0.89%)
USD 81.65
(0.89%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 7.56 Billion USD | -20.12% |
| 2023 | 6.7 Billion USD | 18.44% |
| 2022 | 5.66 Billion USD | -2.33% |
| 2021 | 5.79 Billion AUD | 12.03% |
| 2020 | 5.17 Billion AUD | 9.0% |
| 2019 | 4.74 Billion AUD | 17.07% |
| 2018 | 4.05 Billion AUD | 23.33% |
| 2017 | 3.28 Billion AUD | 14.41% |
| 2016 | 2.87 Billion AUD | 0.77% |
| 2015 | 2.85 Billion AUD | 4.46% |
| 2014 | 2.73 Billion AUD | 6.71% |
| 2013 | 2.55 Billion AUD | 16.87% |
| 2012 | 2.18 Billion AUD | -0.49% |
| 2011 | 2.2 Billion AUD | 14.0% |
| 2010 | 1.93 Billion AUD | 7.59% |
| 2009 | 1.79 Billion AUD | 15.17% |
| 2008 | 1.55 Billion AUD | 27.98% |
| 2007 | 1.21 Billion AUD | 43.13% |
| 2006 | 850.29 Million AUD | 4.89% |
| 2005 | 810.65 Million AUD | 98.43% |
| 2004 | 408.52 Million AUD | 25.27% |
| 2003 | 326.11 Million AUD | 9.45% |
| 2002 | 297.94 Million AUD | -19.32% |
| 2001 | 369.3 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | -100.0% |
| 1997 | 318.09 Million AUD | 13.16% |
| 1996 | 281.1 Million AUD | 12.25% |
| 1995 | 250.43 Million AUD | 29.76% |
| 1994 | 192.99 Million AUD | 15.09% |
| 1993 | 167.69 Million AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | 3.02 Billion USD | 0.0% |
| 2024 FY | 7.56 Billion USD | 12.72% |
| 2024 Q1 | 3.36 Billion USD | 26.39% |
| 2024 Q2 | 4.11 Billion USD | 0.0% |
| 2023 Q1 | 3.01 Billion USD | 35.98% |
| 2023 FY | 6.7 Billion USD | 18.44% |
| 2023 Q4 | 2.66 Billion USD | 19.56% |
| 2023 Q3 | 2.22 Billion USD | -39.59% |
| 2023 Q2 | 3.69 Billion USD | 22.48% |
| 2022 Q4 | 2.21 Billion USD | 45.22% |
| 2022 Q2 | 3.37 Billion USD | 41.27% |
| 2022 FY | 5.66 Billion USD | -2.33% |
| 2022 Q3 | 1.52 Billion USD | -54.74% |
| 2022 Q1 | 2.38 Billion USD | 7.52% |
| 2021 Q4 | 2.21 Billion USD | 42.19% |
| 2021 Q3 | 1.56 Billion USD | -54.2% |
| 2021 Q1 | 2.42 Billion USD | 1.81% |
| 2021 Q2 | 3.4 Billion USD | 40.52% |
| 2021 FY | 5.79 Billion AUD | 12.03% |
| 2020 Q4 | 2.38 Billion USD | 22.86% |
| 2020 FY | 5.17 Billion AUD | 9.0% |
| 2020 Q2 | 2.77 Billion USD | 31.63% |
| 2020 Q1 | 2.1 Billion USD | 0.33% |
| 2020 Q3 | 1.93 Billion USD | -30.02% |
| 2019 Q3 | 1.51 Billion USD | -18.51% |
| 2019 FY | 4.74 Billion AUD | 17.07% |
| 2019 Q1 | 1.81 Billion USD | 32.59% |
| 2019 Q4 | 2.09 Billion AUD | 38.28% |
| 2019 Q2 | 1.86 Billion USD | 2.61% |
| 2018 Q2 | 1.51 Billion USD | 0.5% |
| 2018 Q3 | 1.31 Billion USD | -12.73% |
| 2018 Q4 | 1.36 Billion AUD | 3.8% |
| 2018 FY | 4.05 Billion AUD | 23.33% |
| 2018 Q1 | 1.5 Billion USD | 34.7% |
| 2017 Q2 | 1.31 Billion USD | 6.07% |
| 2017 Q1 | 1.24 Billion USD | 18.94% |
| 2017 FY | 3.28 Billion AUD | 14.41% |
| 2017 Q4 | 1.11 Billion AUD | -0.6% |
| 2017 Q3 | 1.12 Billion USD | -14.81% |
| 2016 Q3 | 1.01 Billion USD | -2.07% |
| 2016 Q4 | 1.04 Billion AUD | 3.17% |
| 2016 FY | 2.87 Billion AUD | 0.77% |
| 2016 Q2 | 1.03 Billion USD | -3.47% |
| 2016 Q1 | 1.07 Billion USD | 11.99% |
| 2015 Q3 | 965.07 Million USD | 14.4% |
| 2015 Q2 | 843.58 Million USD | 6.9% |
| 2015 Q1 | 789.11 Million USD | 7.25% |
| 2015 FY | 2.85 Billion AUD | 4.46% |
| 2015 Q4 | 956.38 Million AUD | -0.9% |
| 2014 Q3 | 748.4 Million USD | -0.32% |
| 2014 FY | 2.73 Billion AUD | 6.71% |
| 2014 Q1 | 718.4 Million USD | 3.93% |
| 2014 Q4 | 735.77 Million AUD | -1.69% |
| 2014 Q2 | 750.83 Million USD | 4.51% |
| 2013 FY | 2.55 Billion AUD | 16.87% |
| 2013 Q2 | 622.86 Million USD | -0.06% |
| 2013 Q4 | 691.23 Million AUD | 13.7% |
| 2013 Q1 | 623.25 Million USD | 0.0% |
| 2013 Q3 | 607.96 Million USD | -2.39% |
| 2012 FY | 2.18 Billion AUD | -0.49% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 FY | 2.2 Billion AUD | 14.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | 1.93 Billion AUD | 7.59% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | 1.79 Billion AUD | 15.17% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | 1.55 Billion AUD | 27.98% |
| 2007 FY | 1.21 Billion AUD | 43.13% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | 850.29 Million AUD | 4.89% |
| 2005 FY | 810.65 Million AUD | 98.43% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 FY | 408.52 Million AUD | 25.27% |
| 2004 Q4 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | 326.11 Million AUD | 9.45% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 FY | 297.94 Million AUD | -19.32% |
| 2001 FY | 369.3 Million AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | -100.0% |
| 1998 Q4 | - AUD | 0.0% |
| 1997 FY | 318.09 Million AUD | 13.16% |
| 1997 Q4 | - AUD | 0.0% |
| 1996 FY | 281.1 Million AUD | 12.25% |
| 1995 FY | 250.43 Million AUD | 29.76% |
| 1994 FY | 192.99 Million AUD | 15.09% |
| 1993 FY | 167.69 Million AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 310004200.041% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -64490.808% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 2366558.325% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -6248.043% |
| Qrons Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 29408.474% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 15667643.878% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 6085362.895% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -50310.027% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -243745870.342% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -77100.327% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -11503368.841% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 22140656.369% |
| Mesoblast Limited | -35.16 Million USD | 21599.659% |
| Marizyme, Inc. | 457.7 Thousand USD | -1651848.211% |
| Genus plc | 178.7 Million USD | -4131.114% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | -3335.194% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -12150769.412% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1843304.484% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 68736463.636% |
| ContraFect Corporation | -154 Thousand USD | 4909840.26% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 15122100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -9849954.064% |
| IMV Inc. | -962.29 Thousand USD | 785823.341% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 1951320.771% |
| MultiCell Technologies, Inc. | 49.32 USD | -15330494628.305% |
| ONE Bio Corp. | 20.12 Million USD | -37469.363% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -18678.095% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -15462067.689% |
| Q BioMed Inc. | -8988.00 USD | 84123375.478% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -26659.866% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 49021106.224% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -16945.475% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 662432.293% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -10801328.571% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 152685883.522% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -5381394.662% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 7753778.921% |
| GB Sciences, Inc. | -624.00 USD | 1211698817.949% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 8789098.931% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 3635096253.846% |
| Enzolytics Inc. | 30.7 Thousand USD | -24622148.274% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -1567164.263% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | -582.105% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 1469653.556% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -1224583.503% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | -1746.159% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 85377245.438% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 9017500.327% |
| Kadimastem Ltd | -630.13 Thousand USD | 1199995.896% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -765198.118% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -78570.274% |
| BioStem Technologies, Inc. | 15.42 Million USD | -48918.314% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 63886876.51% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -4282296.919% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -4282296.919% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -557026.257% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 26072513.793% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -1679961.683% |
| SYBLEU INC | 11.69 Thousand USD | -64645932.832% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -163984.201% |
| Bioxytran, Inc. | -8285.00 USD | 91261415.631% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 2027177.748% |
| Neutra Corp. | 14.33 Thousand USD | -52744929.648% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 9220831.707% |
| PureTech Health plc | -1.6 Million USD | 471778.104% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 755266.614% |
| IXICO plc | 3.27 Million USD | -231123.242% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 1089581.268% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 422266.387% |
| CSL Limited | 7.7 Billion USD | 1.869% |
| Cellectis S.A. | 18 Thousand USD | -42005455.556% |